Pfizer's Fragmin, or dalteparin sodium, was approved by the FDA to lessen the recurrence of symptomatic venous thromboembolism in pediatric patients at least 1 month old. The drug was first approved for adult patients with certain types of angina, deep vein thrombosis and symptomatic VTE.
Pfizer's Fragmin OK'd for pediatric symptomatic VTE
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.